Engineered immune cells take on tough blood cancers in early trial

NCT ID NCT06492304

Completed Disease control Sponsor: CRISPR Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new treatment called CTX131 for adults with certain blood cancers (T-cell lymphoma, B-cell lymphoma, or acute myeloid leukemia) that had returned or stopped responding to standard therapy. CTX131 uses a patient's own immune cells, modified with CRISPR gene editing, to target and attack cancer cells. The main goals were to check the treatment's safety and see if it could shrink or eliminate tumors. The trial involved 12 participants across multiple hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia B-cell neoplasm B-cell non-Hodgkin lymphoma leukemia T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA B CELL LYMPHOMA T-CELL LYMPHOMA

Contacts and locations

Show contact details

Locations

Research Site 1

Houston, Texas, 77030, United States
Research Site 2

The Bronx, New York, 10467, United States
Research Site 3

Boston, Massachusetts, 02114, United States
Research Site 4

New York, New York, 10065, United States
Research Site 5

Stanford, California, 94305, United States
Research Site 6

Phoenix, Arizona, 85054, United States
Research Site 7

East Melbourne, Victoria, 3002, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.